Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Sanofi will pay Nurix Therapeutics $55 million up front and up to $2.5 billion in future milestones to collaborate on targeted protein degradation therapies. Nurix will use DNA-encoded libraries and E3 ligases to create small molecules designed to induce degradation—rather than mere inhibition—of three specified protein drug targets. Nurix signed a similar deal with Gilead Sciences in June that was focused on cancer and other diseases. Biotech firms like Arvinas and Kymera Therapeutics are also developing protein degraders
This article has been sent to the following recipient: